scispace - formally typeset
V

Vincent Cottin

Researcher at Claude Bernard University Lyon 1

Publications -  675
Citations -  29630

Vincent Cottin is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 68, co-authored 574 publications receiving 21594 citations. Previous affiliations of Vincent Cottin include University of Lyon & Institut national de la recherche agronomique.

Papers
More filters
Journal ArticleDOI

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry.

Marius M. Hoeper, +282 more
- 01 Feb 2021 - 
TL;DR: Final data from EXPERT show that in patients with PAH, the safety of riociguat in clinical practice was consistent with clinical trials, with no new safety concerns identified and a lower exposure-adjusted rate of hemoptysis/pulmonary hemorrhage than in the long-term extension of the Phase 3 trial in PAH.

Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials

Vincent Cottin, +8 more
TL;DR: The INPULSIS™ trial as mentioned in this paper was two replicaterandomized, placebo-controlled 52-week Phase III trials that assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with IPF.
Journal ArticleDOI

Update on bioagent therapy in sarcoidosis

Vincent Cottin
- 24 Feb 2010 - 
TL;DR: Infliximab may modestly improve lung function in patients with active disease resistant to steroids, and may be considered in a limited number of patients with severe extrapulmonary systemic manifestations of sarcoidosis, with careful individual evaluation of the risk-benefit ratio.
Journal ArticleDOI

Nonspecific interstitial pneumonia: time to be more specific?

Athol U. Wells, +1 more
- 01 Sep 2016 - 
TL;DR: The concept of idiopathic NSIP as a grouping of separate disorders with a common histologic pattern provides a template for potentially important pathogenetic insights.
Journal ArticleDOI

Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial

Vincent Cottin, +9 more
- 07 Apr 2022 - 
TL;DR: The adverse event profile of nintedanib in patients with progressive fibrosing interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF) was consistent with its established safety and tolerability profile as mentioned in this paper .